Deborah Lindquist

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.4K citations · Full text

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

David Cameron, Michelle Casey, Michael F. Press et al. · Breast Cancer Research and Treatment · 2008 · 801 citations

Breast Oncology, Oncology, Medicine +8

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study

Stephen E. Jones, Rufus Collea, Devchand Paul et al. · The Lancet Oncology · 2013 · 134 citations

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

Paul E. Goss, Ian E. Smith, Joyce O’Shaughnessy et al. · The Lancet Oncology · 2012 · 130 citations

Breast Oncology, Adjuvant Lapatinib, Medicine +5